Medical Genetics in Ophthalmology: Through the Lens of Genetics-Informed Therapies OnDemand-Panel Discussion

Panel Discussion – Concluding Remarks

Video Transcription

Video Summary

The panel discussed the distinction between approved treatments like Luxterna and ongoing clinical trials, emphasizing transparency to avoid therapeutic misconception among patients. Genetic testing in patient registries often involves genetic counselors, though physician data isn’t always collected. They highlighted promising gene therapies and small molecules that not only slow degeneration but sometimes improve vision, advocating for patient storytelling to influence pharmaceutical persistence despite setbacks. Challenges remain in matching treatments to patient populations and disease stages. The session concluded with encouragement to attend Dr. Eric Pierce’s upcoming talk, underscoring the importance of advocacy and continued research in vision therapies.

Keywords

Luxterna

clinical trials

gene therapy

genetic testing

vision therapies